The relationship between serum NT-proBNP levels and severity of coronary artery disease assessed by SYNTAX score in patients with acute myocardial infarction

Background/aim: In the present study, we aimed to investigate the relationship between NT-proBNP and SYNTAX score, which is ameasure of the complexity of coronary artery disease.Materials and methods: We enrolled 405 consecutive patients with myocardial infarction who underwent coronary angiographicexamination. Patients were divided into 3 groups according to their SYNTAX scores. Those with SYNTAX score ≤22 were included inthe low SYNTAX score group (LSTX), those with a score of 23–32 were included in the intermediate SYNTAX score group (ISTX), andthose with a score of ≥33 were included in the high SYNTAX score group (HSTX).Results: NT-proBNP levels were found to be significantly higher in the HSTX group compared to the other groups (P < 0.001) and inthe ISTX group compared to the LSTX group (P < 0.001). The NT-proBNP levels demonstrated an increase from low SYNTAX score tohigh SYNTAX score tertiles.Conclusions: NT-ProBNP levels in patients with myocardial infarction on admission were independently associated with extent,severity, and complexity of coronary atherosclerosis as assessed by SYNTAX score.

PDF

___

1. Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005; 1: 219-227.
2. Garg S, Sarno G, Serruys PW, Rodriguez AE, Bolognese L et al. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single HighDose Bolus Tirofiban Versus Abciximab with SirolimusEluting Stent or Bare-Metal Stent in Acute Myocardial Infarction study) trials. JACC Cardiovascular Interventions. 2011; 4: 66-75.
3. Magro M, Nauta ST, Simsek C, Boersma E, van der Heide E et al. Usefulness of the SYNTAX score to predict “no reflow” in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. American Journal of Cardiology. 2012; 109: 601-606.
4. Kang J, Park KW, Han JK, Yang HM, Kang HJ et al. Usefulness of the baseline Syntax score to predict 3-year outcome after complete revascularization by percutaneous coronary intervention. American Journal of Cardiology 2016; 118: 641- 646.
5. He C, Song Y, Wang CS, Yao Y, Tang XF et al. Prognostic value of the clinical SYNTAX Score on 2-year outcomes in patients with acute coronary syndrome who underwent percutaneous coronary intervention. American Journal of Cardiology 2017; 119: 1493-1499.
6. Altun B, Turkon H, Tasolar H, Beggi H, Altun M et al. The relationship between high-sensitive troponin T, neutrophil lymphocyte ratio and SYNTAX Score. Scandinavian Journal of Clinical and Laboratory Investigation 2014; 74: 108-115.
7. Lin T, Wang L, Guo J, Liu P, Chen L et al. Association between serum LDL-C and ApoB and SYNTAX Score in patients with stable coronary artery disease. Angiology 2018: 69 (8): 724- 729.
8. Ertem AG, Efe TH, Yayla Ç, Akboğa MK, Açar B et al. The association between serum procalcitonin levels and severity of coronary artery disease assessed by SYNTAX score in patients with acute coronary syndrome. Angiology 2017; 68: 40-45.
9. Duran M, Kalay N, Akpek M, Orscelik O, Elcik D et al. High levels of serum uric acid predict severity of coronary artery disease in patients with acute coronary syndrome. Angiology 2012; 63: 448-452.
10. Karadeniz M, Duran M, Akyel A, Yarlıoğlueş M, Öcek AH et al. High sensitive CRP level is associated with intermediate and high syntax score in patients with acute coronary syndrome. International Heart Journal 2015; 56: 377-380.
11. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. New England Journal of Medicine 2002; 347: 161-167.
12. Adnan Nadir M, Dow E, Davidson J, Kennedy N, Lang CC et al. Myocardial ischaemia is associated with an elevated brain natriuretic pepide level even in the presence of left ventricular systolic dysfunction. European Journal of Heart Failure 2014; 16: 56-67.
13. Tsai W, Chien DK, Huang CH, Shih SC, Chang WH. Multiple cardiac biomarkers used in clinical guideline for elderly patients with acute coronary syndrome. International Journal of Gerontology 2017; 11: 104-108.
14. Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993; 88: 82-91.
15. Irzmański R, Piechota M, Barylski M, Banach M, Gławęda B et al. Dynamics of changes of the BNP concentration in patients with stable angina pectoris qualified for PTCA. Dependence on the selected morphological and haemodynamic parameters. Archives of Medical Science 2006; 2: 15-19.
16. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. European Journal of Clinical Investigation 2010; 40: 35-53.
17. Liang F, Gardner DG. Mechanical strain activates BNP gene transcription through a p38/NF-κB-dependent mechanism. Journal of Clinical Investigation 1999; 104: 1603-1612.
18. Tokola H, Hautala N, Marttila M, Magga J, Pikkarainen S et al. Mechanical load-induced alterations in B-type natriuretic peptide gene expression. Canadian Journal of Physiology and Pharmacology 2001; 79: 646-653.
19. Vanderheyden M, Goethals M, Verstreken S, De Bruyne B, Muller K et al. Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. Journal of the American College of Cardiology 2004; 44: 2349-2354.
20. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. American Heart Journal 1998; 135: 825-832.
21. Yamamoto K, Burnett JC, Jougasaki M, Nishimura RA, Bailey KR et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28: 988-994.
22. Tang WW, Girod JP, Lee MJ, Starling RC, Young JB et al. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation 2003; 108: 2964-2966.
23. Kang Q, Zheng W, Huang Z. N-terminal probrain natriuretic peptide in patients with acute coronary syndrome. International Journal of Clinical Pharmacology and Therapeutics 2017; 55: 78.
24. Mega JL, Morrow DA, De Lemos JA, Sabatine MS, Murphy SA et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction. An ENTIRE–TIMI-23 substudy. Journal of the American College of Cardiology 2004; 44: 335-339.
25. De Antonio M, Lupon J, Galan A, Vila J, Urrutia A et al. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure. American Heart Journal 2012; 163: 821-828.
26. Galvani M, Ottani F, Oltrona L, Ardissino D, Gensini GF et al. N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation 2004; 110: 128-134.
27. Serruys PW, Onuma Y, Garg S, Sarno G, van den Brand M et al. Assessment of the SYNTAX score in the SYNTAX study. EuroIntervention. 2009; 5: 50-56.
28. Akgun T, Oduncu V, Bitigen A, Karabay CY, Erkol A et al. Baseline SYNTAX score and long-term outcome in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Clinical and Applied Thrombosis/Hemostasis. 2015; 21: 712-719.
29. Palmerini T, Genereux P, Caixeta A, Cristea E, Lansky A et al. Prognostic value of the SYNTAX score in patients with acute coronary syndromes undergoing percutaneous coronary intervention: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage StrategY) trial. Journal of the American College of Cardiology 2011; 57: 2389- 2397.
30. Valgimigli M, Serruys PW, Tsuchida K, Vaina S, Morel MA et al. Cyphering the complexity of coronary artery disease using the Syntax score to predict clinical outcome in patients with three-vessel lumen obstruction undergoing percutaneous coronary intervention. American Journal of Cardiology. 2007; 99: 1072-1081.
31. Bertrand ME, Lablanche JM, Fourrier JL, Traisnel G, Mirsky I. Left ventricular systolic and diastolic function during acute coronary artery balloon occlusion in humans. Journal of the American College of Cardiology 1988; 12: 341-347.
32. Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology 1993; 132: 1961-1970.
33. Möllmann H, Nef HM, Kostin S, Dragu A, Maack C et al. Ischemia triggers BNP expression in the human myocardium independent from mechanical stress. International Journal of Cardiology. 2010; 143: 289-297.
34. Goetze J, Christoffersen C, Perko M, Arendrup H, Rehfeld J et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB Journal 2003; 17: 1105-1107.
35. Kuwahara K, Saito Y, Harada M, Ishikawa M, Ogawa E et al. Involvement of cardiotrophin-1 in cardiac myocytenonmyocyte interactions during hypertrophy of rat cardiac myocytes in vitro. Circulation 1999; 100: 1116-1124.
36. Harada M, Saito Y, Nakagawa O, Miyamoto Y, Ishikawa M et al. Role of cardiac nonmyocytes in cyclic mechanical stretchinduced myocyte hypertrophy. Heart and Vessels 1997: 198-200.